VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Ianalumab add-on therapy in CLL patients receiving ibrutinib

Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells. It is hoped that its addition to ibrutinib will deepen responses through synergistic activity, allowing discontinuation of ibrutinib and prevention of cumulative toxicity. Patients were enrolled who had developed ibrutinib resistance, or not achieved a complete remission with over 1 year of treatment. The trial has shown manageable safety and promising preliminary efficacy results, with 20% achieving measurable residual disease (MRD) negativity and discontinuing therapy. Investigations into the combination are ongoing. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.


Consultancy: AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Yingli Pharmaceuticals
Research Grants: AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem
All payments made to Sarah Cannon Research Institute, not to the physician

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter